Skip to main content
. Author manuscript; available in PMC: 2014 Jun 15.
Published in final edited form as: Cancer Res. 2013 Apr 2;73(12):3683–3691. doi: 10.1158/0008-5472.CAN-13-0110

Figure 5. ATR inhibition further sensitizes cells with defective HR to cisplatin, topotecan, and veliparib.

Figure 5

(A) OVCAR-8 cells that have stably integrated DR-GFP HR substrate were transfected with pCβASceI plasmid plus control (Luc) or ATR siRNA and examined for GFP fluorescence 72 h after plasmid transfection. Mean +/− S.D; n = 3; *P = 0.02 by paired t-test. * indicates nonspecific band. OVCAR-8 (B–F) or SKOV3 (G) cells were transfected with control (Luc) or BRCA1 siRNA. 48 h after transfection, cells were trypsinized and used to analyze BRCA1 expression (B, OVCAR-8 cells) and for clonogenic assays (C–G). For clonogenic assays, cells were plated, allowed to adhere for 6 h, and treated 0.3 µM MK-8776 or 1 µM VE-821 plus gemcitabine (C) cisplatin (D), topotecan (E), or veliparib (F, G) for 8 d. A representative experiment from 3 independent experiments is shown.